Shandong Jincheng Pharmaceutical Group Co., Ltd
300233.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | CN¥917,671 | CN¥1,024,635 | CN¥859,028 | CN¥981,084 |
| Short-Term Investments | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Receivables | CN¥703,248 | CN¥794,563 | CN¥803,386 | CN¥684,000 |
| Inventory | CN¥598,864 | CN¥501,282 | CN¥579,217 | CN¥391,322 |
| Other Curr. Assets | CN¥8,612 | CN¥48,579 | CN¥65,866 | CN¥82,763 |
| Total Curr. Assets | CN¥2,258,285 | CN¥2,369,281 | CN¥2,308,149 | CN¥2,139,271 |
| Property Plant & Equip (Net) | CN¥2,309,522 | CN¥2,467,807 | CN¥2,468,672 | CN¥2,092,624 |
| Goodwill | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Intangibles | CN¥754,238 | CN¥842,426 | CN¥805,453 | CN¥764,792 |
| Long-Term Investments | CN¥183,281 | CN¥147,521 | CN¥157,557 | CN¥157,832 |
| Tax Assets | CN¥63,938 | CN¥69,774 | CN¥51,880 | CN¥30,711 |
| Other NC Assets | CN¥35,727 | CN¥19,269 | CN¥34,373 | CN¥89,923 |
| Total NC Assets | CN¥3,346,706 | CN¥3,546,799 | CN¥3,517,934 | CN¥3,135,883 |
| Other Assets | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Total Assets | CN¥5,604,991 | CN¥5,916,079 | CN¥5,826,084 | CN¥5,275,153 |
| Liabilities | – | – | – | – |
| Payables | CN¥552,559 | CN¥824,002 | CN¥726,051 | CN¥515,309 |
| Short-Term Debt | CN¥55,039 | CN¥94,000 | CN¥212,886 | CN¥378,446 |
| Tax Payable | CN¥43,060 | CN¥38,788 | CN¥55,458 | CN¥46,866 |
| Deferred Revenue | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Other Curr. Liab. | CN¥156,382 | CN¥147,998 | CN¥168,075 | CN¥217,709 |
| Total Curr. Liab. | CN¥1,230,975 | CN¥1,600,326 | CN¥1,700,938 | CN¥1,416,442 |
| LT Debt | CN¥351,994 | CN¥346,698 | CN¥271,691 | CN¥208,295 |
| Deferred Rev, NC | CN¥53,879 | CN¥61,595 | CN¥0 | CN¥54,813 |
| Deferred Tax Liab, NC | CN¥129,105 | CN¥122,939 | CN¥126,128 | CN¥92,664 |
| Other NC Liab. | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Total NC Liab. | CN¥541,862 | CN¥534,694 | CN¥465,833 | CN¥419,289 |
| Other Liabilities | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Cap. Leases | CN¥6,883 | CN¥3,461 | CN¥2,019 | CN¥63,518 |
| Total Liabilities | CN¥1,772,837 | CN¥2,135,020 | CN¥2,166,772 | CN¥1,835,731 |
| Equity | – | – | – | – |
| Pref Stock | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Common Stock | CN¥383,875 | CN¥383,875 | CN¥387,411 | CN¥387,411 |
| Retained Earnings | CN¥904,843 | CN¥838,248 | CN¥734,602 | CN¥555,303 |
| AOCI | CN¥205,576 | CN¥0 | CN¥29,331 | CN¥127,476 |
| Other Equity | CN¥0 | CN¥164,313 | CN¥0 | CN¥0 |
| Total Equity | CN¥3,766,982 | CN¥3,714,134 | CN¥3,607,438 | CN¥3,394,465 |
| Supplemental Information | – | – | – | – |
| Minority Interest | CN¥65,172 | CN¥66,926 | CN¥51,874 | CN¥44,956 |
| Total Liab. & Tot. Equity | CN¥5,604,991 | CN¥5,916,079 | CN¥5,826,084 | CN¥5,275,153 |
| Net Debt | -CN¥510,638 | -CN¥583,937 | -CN¥374,451 | -CN¥394,343 |